Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.21
DGX's Cash to Debt is ranked lower than
88% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.75 vs. DGX: 0.21 )
Ranked among companies with meaningful Cash to Debt only.
DGX' s 10-Year Cash to Debt Range
Min: 0.02  Med: 0.09 Max: N/A
Current: 0.21
Equity to Asset 0.40
DGX's Equity to Asset is ranked lower than
77% of the 168 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.60 vs. DGX: 0.40 )
Ranked among companies with meaningful Equity to Asset only.
DGX' s 10-Year Equity to Asset Range
Min: 0.3  Med: 0.44 Max: 0.62
Current: 0.4
0.3
0.62
Interest Coverage 5.89
DGX's Interest Coverage is ranked lower than
83% of the 95 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1009.34 vs. DGX: 5.89 )
Ranked among companies with meaningful Interest Coverage only.
DGX' s 10-Year Interest Coverage Range
Min: 1.82  Med: 6.87 Max: 17.57
Current: 5.89
1.82
17.57
F-Score: 5
Z-Score: 2.79
M-Score: -2.69
WACC vs ROIC
2.49%
8.75%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 13.32
DGX's Operating margin (%) is ranked higher than
83% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.26 vs. DGX: 13.32 )
Ranked among companies with meaningful Operating margin (%) only.
DGX' s 10-Year Operating margin (%) Range
Min: -37.2  Med: 16.27 Max: 20.64
Current: 13.32
-37.2
20.64
Net-margin (%) 6.81
DGX's Net-margin (%) is ranked higher than
75% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.79 vs. DGX: 6.81 )
Ranked among companies with meaningful Net-margin (%) only.
DGX' s 10-Year Net-margin (%) Range
Min: -38.73  Med: 7.53 Max: 11.88
Current: 6.81
-38.73
11.88
ROE (%) 12.33
DGX's ROE (%) is ranked higher than
80% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.52 vs. DGX: 12.33 )
Ranked among companies with meaningful ROE (%) only.
DGX' s 10-Year ROE (%) Range
Min: -4.13  Med: 15.47 Max: 21.63
Current: 12.33
-4.13
21.63
ROA (%) 5.17
DGX's ROA (%) is ranked higher than
76% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.89 vs. DGX: 5.17 )
Ranked among companies with meaningful ROA (%) only.
DGX' s 10-Year ROA (%) Range
Min: -1.6  Med: 6.42 Max: 11.74
Current: 5.17
-1.6
11.74
ROC (Joel Greenblatt) (%) 78.88
DGX's ROC (Joel Greenblatt) (%) is ranked higher than
90% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.36 vs. DGX: 78.88 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
DGX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 11.01  Med: 108.62 Max: 146.32
Current: 78.88
11.01
146.32
Revenue Growth (3Y)(%) 3.60
DGX's Revenue Growth (3Y)(%) is ranked lower than
58% of the 111 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.10 vs. DGX: 3.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
DGX' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: 8.20 Max: 15.4
Current: 3.6
0
15.4
EBITDA Growth (3Y)(%) 4.10
DGX's EBITDA Growth (3Y)(%) is ranked higher than
54% of the 100 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.90 vs. DGX: 4.10 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
DGX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: 10.40 Max: 44.5
Current: 4.1
0
44.5
EPS Growth (3Y)(%) 9.90
DGX's EPS Growth (3Y)(%) is ranked higher than
64% of the 99 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.60 vs. DGX: 9.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
DGX' s 10-Year EPS Growth (3Y)(%) Range
Min: 0  Med: 9.65 Max: 62.3
Current: 9.9
0
62.3
» DGX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

DGX Guru Trades in Q3 2014

Joel Greenblatt 238,057 sh (+5330.13%)
Ray Dalio 15,626 sh (+15.36%)
Chuck Royce 213,000 sh (+13.60%)
Murray Stahl 7,750 sh (+9.93%)
Chris Davis 4,879,416 sh (+4.42%)
Manning & Napier Advisors, Inc 195,674 sh (+1.16%)
Bernard Horn 61,733 sh (unchged)
Robert Olstein 82,000 sh (unchged)
Brian Rogers 3,000,000 sh (unchged)
Diamond Hill Capital Sold Out
Scott Black Sold Out
Steven Cohen Sold Out
Paul Tudor Jones Sold Out
Louis Moore Bacon Sold Out
Jeff Auxier 78,950 sh (-0.06%)
Richard Pzena 429,700 sh (-0.32%)
John Rogers 348,910 sh (-1.14%)
David Dreman 33,898 sh (-5.79%)
HOTCHKIS & WILEY 1,593,262 sh (-36.86%)
» More
Q4 2014

DGX Guru Trades in Q4 2014

John Hussman 200,000 sh (New)
Jim Simons 850,700 sh (New)
Paul Tudor Jones 9,600 sh (New)
Charles Brandes 186,113 sh (New)
Ray Dalio 53,126 sh (+239.98%)
Chuck Royce 276,800 sh (+29.95%)
John Rogers 386,508 sh (+10.78%)
Chris Davis 5,155,683 sh (+5.66%)
Bernard Horn 61,733 sh (unchged)
Manning & Napier Advisors, Inc 195,674 sh (unchged)
Brian Rogers 3,000,000 sh (unchged)
Richard Pzena Sold Out
Murray Stahl 7,650 sh (-1.29%)
David Dreman 32,431 sh (-4.33%)
Jeff Auxier 74,800 sh (-5.26%)
Robert Olstein 59,000 sh (-28.05%)
HOTCHKIS & WILEY 983,900 sh (-38.25%)
Joel Greenblatt 88,219 sh (-62.94%)
» More
Q1 2015

DGX Guru Trades in Q1 2015

Pioneer Investments 562,413 sh (New)
Ray Dalio 148,088 sh (+178.75%)
Paul Tudor Jones 14,444 sh (+50.46%)
John Rogers 515,958 sh (+33.49%)
John Hussman 220,000 sh (+10.00%)
Bernard Horn 61,733 sh (unchged)
Manning & Napier Advisors, Inc 195,674 sh (unchged)
Robert Olstein Sold Out
HOTCHKIS & WILEY Sold Out
Chris Davis 5,068,925 sh (-1.68%)
Murray Stahl 7,500 sh (-1.96%)
Charles Brandes 174,714 sh (-6.12%)
Jim Simons 584,100 sh (-31.34%)
David Dreman 21,554 sh (-33.54%)
Joel Greenblatt 56,784 sh (-35.63%)
Brian Rogers 1,750,000 sh (-41.67%)
Chuck Royce 117,000 sh (-57.73%)
Jeff Auxier 23,233 sh (-68.94%)
» More
Q2 2015

DGX Guru Trades in Q2 2015

Manning & Napier Advisors, Inc Sold Out
Brian Rogers Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with DGX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Quest Diagnostics Inc

Bernard Horn Comments on Quest Diagnostics - Aug 07, 2014

The world’s largest provider of medical testing services, Quest Diagnostics (DGX), saw its share price rise after announcing its partnership with Memorial Sloan Kettering in New York to screen patients’ cancer genes for genetic mutations.

From Bernard Horn (Trades, Portfolio)’s Polaris Global Value Fund Second Quarter 2014 Shareholder Letter.

Check out Bernard Horn latest stock trades

Diamond Hill Capital Comments on Quest Diagnostics - Mar 05, 2014

Medical diagnostic testing provider Quest Diagnostics, Inc. (NYSE:DGX) underperformed due to weakness in both volumes and pricing.



From Diamond Hill Capital (Trades, Portfolio)'s Fourth Quarter 2013 Commentary.

Check out Diamond Hill Capital latest stock trades

Top Ranked Articles about Quest Diagnostics Inc

Charles Brandes' Top Buys During Q4
Charles Brandes (Trades, Portfolio) founded Brandes Investment Partners in 1974, which manages a variety of global equity and fixed-income assets for investors worldwide. Read more...
A Look at John Hussman's Recent Additions to His Portfolio
John Hussman (Trades, Portfolio) of Hussman Strategic Advisors, Inc. is known for not holding back on sharing his opinions about the government's handling of the nation's financial state. He has openly criticized the U.S. Treasury and the Federal Reserve. He is also known for predicting the U.S. Recession in 2008-2009 and since the end of 2009, he has been calling for another financial crisis to come along due to the poor policy choices made by the government. Read more...
DGX: A Healthy Diagnosis
How much are you paying for the revenue of companies in your portfolio? The less you pay per dollar of revenue, the better. Why? Because revenue translates into earning power, and as we know, when earnings grow, they pull up stock prices. As with almost any asset, buying for less is best if it's an investment of some kind. Read more...
The Top Five Guru-Held Mid-Cap Stocks of Q2
Using the GuruFocus Aggregated Portfolio Screener you can filter results to see what companies maintain the highest amount of guru ownership. By using this screener, we filtered down to see mid-cap companies which are held by the most gurus. The following five mid-capped companies are held by the largest number of gurus during the past quarter. Read more...
Bernard Horn Comments on Quest Diagnostics
The world’s largest provider of medical testing services, Quest Diagnostics (DGX), saw its share price rise after announcing its partnership with Memorial Sloan Kettering in New York to screen patients’ cancer genes for genetic mutations. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 21.19
DGX's P/E(ttm) is ranked higher than
77% of the 79 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.10 vs. DGX: 21.19 )
Ranked among companies with meaningful P/E(ttm) only.
DGX' s 10-Year P/E(ttm) Range
Min: 9.14  Med: 18.07 Max: 31.21
Current: 21.19
9.14
31.21
Forward P/E 14.45
DGX's Forward P/E is ranked higher than
79% of the 58 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.00 vs. DGX: 14.45 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 21.10
DGX's PE(NRI) is ranked higher than
77% of the 80 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.10 vs. DGX: 21.10 )
Ranked among companies with meaningful PE(NRI) only.
DGX' s 10-Year PE(NRI) Range
Min: 9.53  Med: 16.72 Max: 22.94
Current: 21.1
9.53
22.94
P/B 2.53
DGX's P/B is ranked higher than
68% of the 167 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.58 vs. DGX: 2.53 )
Ranked among companies with meaningful P/B only.
DGX' s 10-Year P/B Range
Min: 1.85  Med: 2.58 Max: 4.43
Current: 2.53
1.85
4.43
P/S 1.41
DGX's P/S is ranked higher than
80% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.95 vs. DGX: 1.41 )
Ranked among companies with meaningful P/S only.
DGX' s 10-Year P/S Range
Min: 1.03  Med: 1.37 Max: 2.24
Current: 1.41
1.03
2.24
PFCF 17.78
DGX's PFCF is ranked higher than
84% of the 63 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 28.48 vs. DGX: 17.78 )
Ranked among companies with meaningful PFCF only.
DGX' s 10-Year PFCF Range
Min: 8.22  Med: 13.80 Max: 21.5
Current: 17.78
8.22
21.5
POCF 11.98
DGX's POCF is ranked higher than
84% of the 76 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.03 vs. DGX: 11.98 )
Ranked among companies with meaningful POCF only.
DGX' s 10-Year POCF Range
Min: 6.98  Med: 10.90 Max: 14.43
Current: 11.98
6.98
14.43
EV-to-EBIT 15.13
DGX's EV-to-EBIT is ranked higher than
72% of the 89 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.73 vs. DGX: 15.13 )
Ranked among companies with meaningful EV-to-EBIT only.
DGX' s 10-Year EV-to-EBIT Range
Min: 7.3  Med: 10.90 Max: 15.4
Current: 15.13
7.3
15.4
PEG 5.86
DGX's PEG is ranked lower than
73% of the 37 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.12 vs. DGX: 5.86 )
Ranked among companies with meaningful PEG only.
DGX' s 10-Year PEG Range
Min: 0.65  Med: 1.39 Max: 4.49
Current: 5.86
0.65
4.49
Shiller P/E 18.28
DGX's Shiller P/E is ranked higher than
85% of the 53 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 27.91 vs. DGX: 18.28 )
Ranked among companies with meaningful Shiller P/E only.
DGX' s 10-Year Shiller P/E Range
Min: 12.73  Med: 18.62 Max: 39.21
Current: 18.28
12.73
39.21
Current Ratio 1.14
DGX's Current Ratio is ranked lower than
87% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.68 vs. DGX: 1.14 )
Ranked among companies with meaningful Current Ratio only.
DGX' s 10-Year Current Ratio Range
Min: 0.74  Med: 1.25 Max: 2.15
Current: 1.14
0.74
2.15
Quick Ratio 1.09
DGX's Quick Ratio is ranked lower than
84% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.31 vs. DGX: 1.09 )
Ranked among companies with meaningful Quick Ratio only.
DGX' s 10-Year Quick Ratio Range
Min: 0.7  Med: 1.17 Max: 2.03
Current: 1.09
0.7
2.03
Days Inventory 8.31
DGX's Days Inventory is ranked higher than
92% of the 142 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 77.75 vs. DGX: 8.31 )
Ranked among companies with meaningful Days Inventory only.
DGX' s 10-Year Days Inventory Range
Min: 6.93  Med: 8.24 Max: 13.81
Current: 8.31
6.93
13.81
Days Sales Outstanding 46.01
DGX's Days Sales Outstanding is ranked higher than
76% of the 157 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 65.45 vs. DGX: 46.01 )
Ranked among companies with meaningful Days Sales Outstanding only.
DGX' s 10-Year Days Sales Outstanding Range
Min: 40.51  Med: 46.77 Max: 89.26
Current: 46.01
40.51
89.26

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.93
DGX's Dividend Yield is ranked higher than
69% of the 75 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.43 vs. DGX: 1.93 )
Ranked among companies with meaningful Dividend Yield only.
DGX' s 10-Year Dividend Yield Range
Min: 0.58  Med: 0.80 Max: 2.36
Current: 1.93
0.58
2.36
Dividend Payout 0.39
DGX's Dividend Payout is ranked lower than
57% of the 47 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.34 vs. DGX: 0.39 )
Ranked among companies with meaningful Dividend Payout only.
DGX' s 10-Year Dividend Payout Range
Min: 0.09  Med: 0.14 Max: 0.91
Current: 0.39
0.09
0.91
Dividend growth (3y) 28.20
DGX's Dividend growth (3y) is ranked higher than
76% of the 21 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.50 vs. DGX: 28.20 )
Ranked among companies with meaningful Dividend growth (3y) only.
DGX' s 10-Year Dividend growth (3y) Range
Min: 0  Med: -3.20 Max: 55.4
Current: 28.2
0
55.4
Yield on cost (5-Year) 6.51
DGX's Yield on cost (5-Year) is ranked higher than
94% of the 79 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.55 vs. DGX: 6.51 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
DGX' s 10-Year Yield on cost (5-Year) Range
Min: 1.98  Med: 2.73 Max: 8.05
Current: 6.51
1.98
8.05
Share Buyback Rate 3.30
DGX's Share Buyback Rate is ranked higher than
95% of the 112 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.80 vs. DGX: 3.30 )
Ranked among companies with meaningful Share Buyback Rate only.
DGX' s 10-Year Share Buyback Rate Range
Min: 0  Med: 2.30 Max: -17.7
Current: 3.3

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.04
DGX's Price/Projected FCF is ranked higher than
79% of the 67 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.97 vs. DGX: 1.04 )
Ranked among companies with meaningful Price/Projected FCF only.
DGX' s 10-Year Price/Projected FCF Range
Min: 0.65  Med: 0.82 Max: 4.46
Current: 1.04
0.65
4.46
Price/DCF (Earnings Based) 1.91
DGX's Price/DCF (Earnings Based) is ranked higher than
54% of the 13 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.91 vs. DGX: 1.91 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.04
DGX's Price/Median PS Value is ranked higher than
55% of the 153 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.12 vs. DGX: 1.04 )
Ranked among companies with meaningful Price/Median PS Value only.
DGX' s 10-Year Price/Median PS Value Range
Min: 0.23  Med: 1.00 Max: 1.64
Current: 1.04
0.23
1.64
Price/Peter Lynch Fair Value 4.15
DGX's Price/Peter Lynch Fair Value is ranked lower than
79% of the 28 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.02 vs. DGX: 4.15 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
DGX' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.62  Med: 1.25 Max: 4.33
Current: 4.15
0.62
4.33
Earnings Yield (Greenblatt) (%) 6.65
DGX's Earnings Yield (Greenblatt) (%) is ranked higher than
87% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.10 vs. DGX: 6.65 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
DGX' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 6.5  Med: 9.10 Max: 13.7
Current: 6.65
6.5
13.7
Forward Rate of Return (Yacktman) (%) 11.12
DGX's Forward Rate of Return (Yacktman) (%) is ranked higher than
51% of the 53 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 11.12 vs. DGX: 11.12 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
DGX' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: 10.6  Med: 18.00 Max: 33.6
Current: 11.12
10.6
33.6

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, LIFE, ENZ, IDXX » details
Traded in other countries:QDI.Germany,
Quest Diagnostics Inc was incorporated in Delaware in 1990. The Company and its subsidiaries are the providers of diagnostic testing. The Company operations are organized in two business groups; Diagnostics Information Services and Diagnostic Solutions group. The Diagnostics Information Services business is a provider of diagnostic information services, which includes providing clinical testing services such as routine testing, gene-based and esoteric testing, anatomic pathology services and drugs-of-abuse testing, as well as related services and insights. The Company offers patients, physicians, hospitals, IDNs, health plans, employers and others the broadest access in the United States to diagnostic information services through its nationwide network of laboratories, Company-owned patient service centers and phlebotomists in physician offices. It provides interpretive consultation through the medical and scientific staff in the industry, including over 725 M.D.s and Ph.D.s, located in the United States, many of whom are recognized leaders in their fields, and genetic counselors. Diagnostic Solutions group offers solutions for insurers, healthcare providers and others. The Company is a provider of risk assessment services for the life insurance industry. The Company is a provider of testing for clinical trials. In addition, it offers healthcare organizations and clinicians robust information technology solutions and diagnostic products, including test kits. The Company is subject to or impacted by extensive and frequently changing laws and regulations in the United States (at both the federal and state levels) and the other jurisdictions in which it conducts business.
» More Articles for DGX

Headlines

Articles On GuruFocus.com
Brian Rogers Buys Occidental Petroleum, Tyco In Q2 Jul 16 2015 
Vermillion (VRML) Ovarian Cancer Test Mega-deal; Papa Murphy's Holdings (FRSH) and Wix (WIX) Strong Mar 18 2015 
Charles Brandes' Top Buys During Q4 Feb 11 2015 
A Look at John Hussman's Recent Additions to His Portfolio Feb 06 2015 
DGX: A Healthy Diagnosis Oct 08 2014 
The Top Five Guru-Held Mid-Cap Stocks of Q2 Sep 04 2014 
LabCorp: A Leading Independent Diagnostic Laboratory Aug 22 2014 
Bernard Horn Comments on Quest Diagnostics Aug 07 2014 
Top Five Guru-Owned Mid Cap Stocks Jun 18 2014 
Morning Coffee: Widely Held Guru Stocks Trading Near Historical Low P/S May 28 2014 

More From Other Websites
Quest Diagnostics Collaborates with Perinatal Quality Foundation on National Initiative to Advance... Jul 29 2015
Quest Diagnostics Collaborates with Perinatal Quality Foundation on National Initiative to Advance... Jul 29 2015
Top 10 New Stocks to Trade Like Hedge Fund Renaissance Technologies Jul 29 2015
Quest Diagnostics attracting bulls Jul 28 2015
Your first trade for Tuesday, July 28 Jul 27 2015
Fast Money Final Trade: GMCR, DGX, JPM & X Jul 27 2015
Illumina, Inc. Earnings Analysis: By the Numbers Jul 27 2015
Edited Transcript of DGX earnings conference call or presentation 23-Jul-15 12:30pm GMT Jul 23 2015
Quest Diagnostics (DGX) Earnings Report: Q2 2015 Conference Call Transcript Jul 23 2015
Quest Diagnostics Tops Earnings, Revenues Lag Estimates - Analyst Blog Jul 23 2015
Quest Diagnostics (DGX) Beat on Q2 Earnings; Revenues Lag - Tale of the Tape Jul 23 2015
Quest Diagnostics Inc Earnings Call scheduled for 8:30 am ET today Jul 23 2015
Q2 2015 Quest Diagnostics Inc Earnings Release - Before Market Open Jul 23 2015
QUEST DIAGNOSTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Jul 23 2015
Quest Diagnostics Reports Second Quarter 2015 Financial Results Jul 23 2015
What's in Store at Quest Diagnostics (DGX) this Earnings? - Analyst Blog Jul 21 2015
Sonora Quest Laboratories Empowers Patients Across Arizona to Take Control of Their Health with... Jul 16 2015
A second FDA approval frees Theranos to do a blood test outside lab Jul 16 2015
Quest Diagnostics To Release Second Quarter 2015 Financial Results On July 23 Jul 07 2015
Quest Diagnostics To Release Second Quarter 2015 Financial Results On July 23 Jul 07 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK